Ariel Jones

Cancer Nursing Today nonprod

According to results from the ROMEI trial, patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib frequently are nonadherent to treatment, which could negatively impact disease control.The ROMEI trial is a prospective, observational study in 188 patients from real-world practices. Researchers assessed treatment adherence based on the eight-item Morisky Medication Adherence Scale (MMAS-8). The present analysis reports findings at week 24 of treatment.A total of 101 of 188 evaluable patients completed the questionnaire at every visit (defined as &ldquo;full completers&rdquo;). In the overall population, the average total MMAS-8 score remained stable from week 4 to week 24, at 7.54?&plusmn;?0.77 and 7.67?&plusmn;?0.70, respectively. There was a similar trend among full completers (7.53?&plusmn;?0.79 and 7.67?&plusmn;?0.73, respectively). Rates of low adherence (MMAS-8 score ?6) were 25 to 40%, while rates of medium adherence (MMAS-8?score ?6 to ?8) were 26 to 36%. Among full completers, 55 (54%) reported at least one change in adherence category (improvement and/or worsening), &ldquo;most of which were associated with unintentional behavior,&rdquo; the authors noted. &ldquo;The data suggest that one-third of patients receiving ruxolitinib may be undertreated due to nonadherence,&rdquo; the researchers concluded, which potentially undermines disease control. These results also &ldquo;indicate a need for better interventions addressing noncompliance to oral therapies.&rdquo;

Examining Ruxolitinib Adherence Patterns in Patients With Myelofibrosis

Myelofibrosis

According to results from the ROMEI trial, patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib frequently are nonadherent to treatment, which could negatively impact disease control. The ROMEI trial is a prospective, observational study in 188 patients from real-world practices. Researchers assessed treatment adherence based on the eight-item Morisky Medication Adherence Scale (MMAS-8). The [...]

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe